Girard Partners’s Genomic Health, Inc. GHDX Stock Holding History

Girard Partners’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-380	Closed	-$26K	–	935
2018 Q3	$26K	Buy	+380	New	+$22.2K	﹤0.01%	562

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Girard Partners's GHDX Position: Q4 2018 in Review

Girard Partners sold out of Genomic Health, Inc. (GHDX) in Q4 2018, closing a stake of 380 shares — an estimated $26K sold.

Girard Partners first reported a position in GHDX in Q3 2018 and held it in 1 quarter. The position peaked at $26K in Q3 2018. 228 funds tracked by Wall St. Rank hold GHDX as of Q4 2018.

Girard Partners reported no remaining Genomic Health, Inc. position as of Q4 2018 after selling out during the quarter.
Girard Partners sold 380 Genomic Health, Inc. shares in Q4 2018, an estimated $26K.
Girard Partners first reported a position in Genomic Health, Inc. in Q3 2018 and held it in 1 quarter.
Girard Partners's Genomic Health, Inc. position peaked at $26K in Q3 2018.
228 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2018.

Based on Girard Partners's 13F filing for Q4 2018, filed 11 Feb 2019.